Clinical Trials
16 trialsNCT04566328 2026-05-15
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT06182774 2026-05-12
Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT04166565 2026-04-20
EMN19
European Myeloma Network B.V.
Phase 2 Active not recruiting
NCT07107529 2026-04-15
Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
European Myeloma Network B.V.
Phase 2 Recruiting
NCT04667663 2026-04-13
CPD-DARA
Cancer Trials Ireland
Phase 1 Active not recruiting
NCT06918002 2026-04-02
ElLen
Intergroupe Francophone du Myelome
Phase 3 Recruiting
NCT06932562 2026-03-25
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
European Myeloma Network B.V.
Phase 3 Recruiting
NCT05257083 2026-03-17
CARTITUDE-6
European Myeloma Network B.V.
Phase 3 Active not recruiting
NCT03710603 2026-02-10
Perseus
European Myeloma Network B.V.
Phase 3 Active not recruiting
NCT03180736 2025-12-19
EMN14
European Myeloma Network B.V.
Phase 3 Completed
NCT04071457 2025-09-15
DRAMMATIC
SWOG Cancer Research Network
Phase 3 Active not recruiting
NCT03896737 2025-08-11
Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara
European Myeloma Network B.V.
Phase 2 Active not recruiting
NCT05561387 2025-06-04
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
SWOG Cancer Research Network
Phase 3 Recruiting
NCT02541383 2025-04-13
Cassiopeia
Intergroupe Francophone du Myelome
Phase 3 Completed
NCT03732703 2025-02-14
MyDRUG
Multiple Myeloma Research Consortium
Phase 1/2 Completed
NCT06189833 2024-04-23
TAURUS
European Myeloma Network B.V.
Phase 2 Unknown